Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

Abstract Background Radiotherapy may work synergistically with immunotherapy and targeted agents. We aimed to assess the safety and outcomes of stereotactic body radiotherapy (SBRT) plus non-first-line programmed death-1 (PD-1) inhibitors and targeted agents (TA) in metastatic renal cell carcinoma (...

Full description

Bibliographic Details
Main Authors: Yang Liu, Zhiling Zhang, Ruiqi Liu, Wensu Wei, Zitong Zhang, Lixin Mai, Shengjie Guo, Hui Han, Fangjian Zhou, Liru He, Pei Dong
Format: Article
Language:English
Published: BMC 2021-11-01
Series:Radiation Oncology
Subjects:
Renal cell carcinoma
Metastasis
Anti-PD-1 therapy
Targeted therapy
Stereotactic body radiation therapy
Online Access:https://doi.org/10.1186/s13014-021-01937-9

Internet

https://doi.org/10.1186/s13014-021-01937-9

Similar Items